{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:45:07Z","timestamp":1780361107841,"version":"3.54.1"},"reference-count":46,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We investigated whether the outcome prediction of patients with aggressive B-cell lymphoma can be improved by combining clinical, molecular genotype, and radiomics features. MYC, BCL2, and BCL6 rearrangements were assessed using fluorescence in situ hybridization. Seventeen radiomics features were extracted from the baseline positron emission tomography\u2013computed tomography of 323 patients, which included maximum standardized uptake value (SUVmax), SUVpeak, SUVmean, metabolic tumor volume (MTV), total lesion glycolysis, and 12 dissemination features pertaining to distance, differences in uptake and volume between lesions, respectively. Logistic regression with backward feature selection was used to predict progression after 2 years. The predictive value of (1) International Prognostic Index (IPI); (2) IPI plus MYC; (3) IPI, MYC, and MTV; (4) radiomics; and (5) MYC plus radiomics models were tested using the cross-validated area under the curve (CV-AUC) and positive predictive values (PPVs). IPI yielded a CV-AUC of 0.65\u00a0\u00b1 0.07 with a PPV of 29.6%. The IPI plus MYC model yielded a CV-AUC of 0.68\u00a0\u00b1 0.08. IPI, MYC, and MTV yielded a CV-AUC of 0.74\u00a0\u00b1 0.08. The highest model performance of the radiomics model was observed for MTV combined with the maximum distance between the largest lesion and another lesion, the maximum difference in SUVpeak between 2 lesions, and the sum of distances between all lesions, yielding an improved CV-AUC of 0.77\u00a0\u00b1 0.07. The same radiomics features were retained when adding MYC (CV-AUC, 0.77\u00a0\u00b1 0.07). PPV was highest for the MYC plus radiomics model (50.0%) and increased by 20% compared with the IPI (29.6%). Adding radiomics features improved model performance and PPV and can, therefore, aid in identifying poor prognosis patients.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008629","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T17:47:38Z","timestamp":1666979258000},"page":"214-223","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":17,"title":["Baseline radiomics features and <i>MYC<\/i> rearrangement status predict progression in aggressive B-cell lymphoma"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6094-0016","authenticated-orcid":false,"given":"Jakoba J.","family":"Eertink","sequence":"first","affiliation":[{"name":"1Department of Hematology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"2Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9571-9362","authenticated-orcid":false,"given":"Gerben J. C.","family":"Zwezerijnen","sequence":"additional","affiliation":[{"name":"2Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands"},{"name":"3Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-8121","authenticated-orcid":false,"given":"Sanne E.","family":"Wiegers","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"2Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7897-6383","authenticated-orcid":false,"given":"Simone","family":"Pieplenbosch","sequence":"additional","affiliation":[{"name":"2Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands"},{"name":"3Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine E. D.","family":"Chamuleau","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"2Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6735-8651","authenticated-orcid":false,"given":"Pieternella J.","family":"Lugtenburg","sequence":"additional","affiliation":[{"name":"4Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9725-4060","authenticated-orcid":false,"given":"Daphne","family":"de Jong","sequence":"additional","affiliation":[{"name":"2Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands"},{"name":"5Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9479-3010","authenticated-orcid":false,"given":"Bauke","family":"Ylstra","sequence":"additional","affiliation":[{"name":"2Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands"},{"name":"5Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6130-1785","authenticated-orcid":false,"given":"Matias","family":"Mendeville","sequence":"additional","affiliation":[{"name":"2Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands"},{"name":"5Department of Pathology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"D\u00fchrsen","sequence":"additional","affiliation":[{"name":"6Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Hanoun","sequence":"additional","affiliation":[{"name":"6Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2230-3873","authenticated-orcid":false,"given":"Andreas","family":"H\u00fcttmann","sequence":"additional","affiliation":[{"name":"6Department of Hematology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Richter","sequence":"additional","affiliation":[{"name":"7Hematopathology Section, Department of Pathology, University Hospital Schleswig-Holstein, Christian-Albrecht-University of Kiel, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7208-4117","authenticated-orcid":false,"given":"Wolfram","family":"Klapper","sequence":"additional","affiliation":[{"name":"7Hematopathology Section, Department of Pathology, University Hospital Schleswig-Holstein, Christian-Albrecht-University of Kiel, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne W. S.","family":"Jauw","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"2Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands"},{"name":"3Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otto S.","family":"Hoekstra","sequence":"additional","affiliation":[{"name":"2Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands"},{"name":"3Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5454-2804","authenticated-orcid":false,"given":"Henrica C. W.","family":"de Vet","sequence":"additional","affiliation":[{"name":"8Department of Epidemiology and Data Science, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"9Department of Methodology, Amsterdam Public Health, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Boellaard","sequence":"additional","affiliation":[{"name":"2Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands"},{"name":"3Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1074-5922","authenticated-orcid":false,"given":"Jos\u00e9e M.","family":"Zijlstra","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Amsterdam University Medical Center (UMC), Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"},{"name":"2Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"35","key":"2023013115350780500_bib1","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1200\/JCO.19.00743","article-title":"Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium","volume":"37","author":"Rosenwald","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"17","key":"2023013115350780500_bib2","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Savage","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2023013115350780500_bib3","doi-asserted-by":"crossref","first-page":"726","DOI":"10.3324\/haematol.2013.091827","article-title":"Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma","volume":"99","author":"Aukema","year":"2014","journal-title":"Haematologica"},{"issue":"20","key":"2023013115350780500_bib4","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"20","key":"2023013115350780500_bib5","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023013115350780500_bib6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1111\/bjh.14282","article-title":"Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable","volume":"175","author":"Landsburg","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"2023013115350780500_bib7","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1182\/asheducation-2017.1.284","article-title":"Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?","volume":"2017","author":"Davies","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2023013115350780500_bib8","author":"National Comprehensive Cancer Network","year":"2022"},{"issue":"27","key":"2023013115350780500_bib9","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2023013115350780500_bib10","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023013115350780500_bib11","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1007\/s11307-020-01474-z","article-title":"Optimizing workflows for fast and reliable metabolic tumor volume measurements in diffuse large B cell lymphoma","volume":"22","author":"Burggraaff","year":"2020","journal-title":"Mol Imag Biol"},{"issue":"8","key":"2023013115350780500_bib12","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.2967\/jnumed.119.227249","article-title":"Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden","volume":"60","author":"Barrington","year":"2019","journal-title":"J\u00a0Nucl Med"},{"issue":"16","key":"2023013115350780500_bib13","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1182\/blood.2019003526","article-title":"High total metabolic tumor volume at baseline predicts survival independent of response to therapy","volume":"135","author":"Vercellino","year":"2020","journal-title":"Blood"},{"key":"2023013115350780500_bib14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejca.2019.09.027","article-title":"Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: post-hoc analysis from the PETAL trial","volume":"124","author":"Schmitz","year":"2020","journal-title":"Eur J Cancer"},{"issue":"21","key":"2023013115350780500_bib15","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1200\/JCO.21.02063","article-title":"Proposed new dynamic prognostic index for diffuse large B-cell lymphoma: International Metabolic Prognostic Index","volume":"40","author":"Mikhaeel","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023013115350780500_bib16","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1007\/s00259-021-05480-3","article-title":"18F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma","volume":"49","author":"Eertink","year":"2022","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"10","key":"2023013115350780500_bib17","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/bloodadvances.2020001816","article-title":"High metabolic heterogeneity on baseline 18FDG-PET\/CT scan as a poor prognostic factor for newly diagnosed diffuse large B-cell lymphoma","volume":"4","author":"Senjo","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"2023013115350780500_bib18","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1182\/bloodadvances.2019001201","article-title":"SAKK38\/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model","volume":"4","author":"Ceriani","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"2023013115350780500_bib19","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1007\/s00330-020-06815-8","article-title":"Baseline (18)F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy","volume":"30","author":"Aide","year":"2020","journal-title":"Eur Radiol"},{"issue":"10","key":"2023013115350780500_bib20","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1007\/s00259-021-05233-2","article-title":"Baseline PET\/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review","volume":"48","author":"Frood","year":"2021","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"8","key":"2023013115350780500_bib21","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","author":"Scott","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2023013115350780500_bib22","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/bloodadvances.2021004467","article-title":"Optimal timing and criteria of interim PET in DLBCL: a comparative study of 1692 patients","volume":"5","author":"Eertink","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"2023013115350780500_bib23","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.3324\/haematol.2019.238162","article-title":"Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial","volume":"105","author":"Chamuleau","year":"2020","journal-title":"Haematologica"},{"issue":"29","key":"2023013115350780500_bib24","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.19.03418","article-title":"Rituximab-CHOP with early rituximab intensification for diffuse large B-cell lymphoma: a randomized phase III trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)","volume":"38","author":"Lugtenburg","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"20","key":"2023013115350780500_bib25","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2017.76.8093","article-title":"Positron emission tomography-guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial","volume":"36","author":"Duhrsen","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2023013115350780500_bib26","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imag"},{"issue":"3","key":"2023013115350780500_bib27","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2967\/jnumed.119.238923","article-title":"Automated segmentation of baseline metabolic total tumor burden in diffuse large B-cell lymphoma: which method is most successful","volume":"62","author":"Barrington","year":"2021","journal-title":"J\u00a0Nucl Med"},{"issue":"1","key":"2023013115350780500_bib28","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2967\/jnumed.119.229450","article-title":"18F-FDG PET dissemination features in diffuse large B-cell lymphoma are predictive of outcome","volume":"61","author":"Cottereau","year":"2020","journal-title":"J\u00a0Nucl Med"},{"issue":"2","key":"2023013115350780500_bib29","doi-asserted-by":"crossref","first-page":"e0212223","DOI":"10.1371\/journal.pone.0212223","article-title":"An open source and easy to use radiomics calculator tool","volume":"14","author":"Pfaehler","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"2023013115350780500_bib30","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1148\/radiol.2020191145","article-title":"The image biomarker standardization initiative: standardized quantitative radiomics for high-throughput image-based phenotyping","volume":"295","author":"Zwanenburg","year":"2020","journal-title":"Radiology"},{"issue":"14","key":"2023013115350780500_bib31","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2023013115350780500_bib32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"2023013115350780500_bib33","author":"Steyerberg","year":"2009"},{"issue":"1","key":"2023013115350780500_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/hon.2935","article-title":"Generation and validation of a PET radiomics model that predicts survival in diffuse large B cell lymphoma treated with R-CHOP14: a SAKK 38\/07 trial post-hoc analysis","volume":"40","author":"Ceriani","year":"2022","journal-title":"Hematol Oncol"},{"issue":"3","key":"2023013115350780500_bib35","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.annonc.2020.11.019","article-title":"Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET\/CT(dagger)","volume":"32","author":"Cottereau","year":"2021","journal-title":"Ann Oncol"},{"issue":"15","key":"2023013115350780500_bib36","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1158\/1078-0432.CCR-15-2825","article-title":"Molecular profile and FDG-PET\/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma","volume":"22","author":"Cottereau","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"21","key":"2023013115350780500_bib37","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"2023013115350780500_bib38","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"22","key":"2023013115350780500_bib39","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood.V128.22.469.469","article-title":"Phase III randomized study of R-CHOP versus DA-EPOCH-R and molecular analysis of untreated diffuse large b-cell lymphoma: CALGB\/Alliance 50303","volume":"128","author":"Wilson","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2023013115350780500_bib40","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1080\/10428194.2018.1429606","article-title":"Double hit lymphoma: do we need a \u2018double hit\u2019 of intensive therapy?","volume":"59","author":"Villa","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2023013115350780500_bib41","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1007\/s00259-018-3953-z","article-title":"Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma","volume":"45","author":"Ilyas","year":"2018","journal-title":"Eur\u00a0J Nucl Med Mol Imag"},{"issue":"3","key":"2023013115350780500_bib42","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.119.229724","article-title":"Experimental multicenter and multivendor evaluation of the performance of PET radiomic features using 3-dimensionally printed phantom inserts","volume":"61","author":"Pfaehler","year":"2020","journal-title":"J\u00a0Nucl Med"},{"issue":"3","key":"2023013115350780500_bib43","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2967\/jnumed.121.262117","article-title":"Quantitative radiomics features in diffuse large B-cell lymphoma: does segmentation method matter?","volume":"63","author":"Eertink","year":"2022","journal-title":"J\u00a0Nucl Med"},{"key":"2023013115350780500_bib44","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jclinepi.2015.04.005","article-title":"Prediction models need appropriate internal, internal-external, and external validation","volume":"69","author":"Steyerberg","year":"2016","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"3","key":"2023013115350780500_bib45","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/aje\/kwu140","article-title":"Correcting for optimistic prediction in small data sets","volume":"180","author":"Smith","year":"2014","journal-title":"Am J Epidemiol"},{"issue":"1","key":"2023013115350780500_bib46","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13550-022-00931-w","article-title":"External validation: a simulation study to compare cross-validation versus holdout or external testing to assess the performance of clinical prediction models using PET data from DLBCL patients","volume":"12","author":"Eertink","year":"2022","journal-title":"EJNMMI Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/2\/214\/2031501\/blooda_adv-2022-008629-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/2\/214\/2031501\/blooda_adv-2022-008629-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T16:14:05Z","timestamp":1675181645000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/2\/214\/486938\/Baseline-radiomics-features-and-MYC-rearrangement"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,1,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008629","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,24]]}}}